Danaher Reports Third Quarter 2025 Results

Danaher Corporation (NYSE: DHR) reported strong third-quarter 2025 results, exceeding revenue, earnings, and cash flow expectations, driven by robust performance in its bioprocessing business and better-than-anticipated respiratory revenue from Cepheid. The company posted $6.053 billion in sales and diluted EPS of $1.27, with core sales growth of 3.0%, including 6.5% in Biotechnology and 3.5% in Diagnostics. For the full year 2025, Danaher maintained its adjusted diluted net earnings per common share guidance of $7.70 to $7.80, projecting low-single digit non-GAAP core revenue growth.

Analysis

Danaher Corporation (DHR) reported robust third-quarter 2025 results, surpassing revenue, earnings, and cash flow expectations. GAAP sales increased 4.5% year-over-year to $6.053 billion, with diluted EPS rising to $1.27 from $1.12 in Q3 2024. Non-GAAP adjusted diluted EPS also saw a significant increase to $1.89 from $1.71, indicating strong operational execution.

The positive performance was largely propelled by a 6.5% core sales growth in the Biotechnology segment and a 3.5% core sales growth in Diagnostics, which benefited from better-than-anticipated respiratory revenue at Cepheid. Despite a 1.0% core sales decline in the Life Sciences segment, total non-GAAP core sales growth for the quarter was 3.0%. Operating cash flow improved to $1,662 million from $1,513 million, contributing to free cash flow of $1,370 million, up from $1,226 million year-over-year.

For the full year 2025, Danaher maintained its adjusted diluted net EPS guidance range of $7.70 to $7.80, alongside a projection for low-single digit non-GAAP core revenue growth. Management highlighted ongoing investments in innovation, enhanced commercial execution, and productivity gains as key drivers for strengthening its long-term competitive position. The Q4 2025 outlook anticipates low-single digit core sales growth, with Biotechnology expected at ~+5%, Life Sciences at a low-single digit decline, and Diagnostics remaining flat.

Key Decisions for Investors

• Investors should monitor the divergent segmental performance, particularly the recovery trajectory of the Life Sciences segment and sustained growth in Biotechnology and Diagnostics.
• Given the strong cash flow generation and strategic focus on innovation, investors may consider Danaher's long-term growth prospects within the life sciences and diagnostics sectors.
• The maintained full-year guidance, despite strong Q3 beats, suggests a prudent outlook, which investors should incorporate into their valuation assessments and future earnings expectations.